Abbott Laboratories

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABT is priced at $133.26, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABT's ROE is +0.31%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BSX has a market cap of 151.4B. Regarding current trading prices, ABT is priced at $133.26, while BSX trades at $102.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BSX's P/E ratio is 73.64. In terms of profitability, ABT's ROE is +0.31%, compared to BSX's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SYK has a market cap of 144.9B. Regarding current trading prices, ABT is priced at $133.26, while SYK trades at $379.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SYK's P/E ratio is 51.24. In terms of profitability, ABT's ROE is +0.31%, compared to SYK's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, MDT has a market cap of 110.3B. Regarding current trading prices, ABT is priced at $133.26, while MDT trades at $85.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas MDT's P/E ratio is 23.82. In terms of profitability, ABT's ROE is +0.31%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, EW has a market cap of 44.2B. Regarding current trading prices, ABT is priced at $133.26, while EW trades at $75.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas EW's P/E ratio is 31.12. In terms of profitability, ABT's ROE is +0.31%, compared to EW's ROE of +0.49%. Regarding short-term risk, ABT is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, DXCM has a market cap of 31.3B. Regarding current trading prices, ABT is priced at $133.26, while DXCM trades at $79.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas DXCM's P/E ratio is 60.02. In terms of profitability, ABT's ROE is +0.31%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, ABT is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, STE has a market cap of 23.3B. Regarding current trading prices, ABT is priced at $133.26, while STE trades at $236.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas STE's P/E ratio is 38.40. In terms of profitability, ABT's ROE is +0.31%, compared to STE's ROE of +0.09%. Regarding short-term risk, ABT is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, PODD has a market cap of 21.7B. Regarding current trading prices, ABT is priced at $133.26, while PODD trades at $307.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas PODD's P/E ratio is 55.44. In terms of profitability, ABT's ROE is +0.31%, compared to PODD's ROE of +0.35%. Regarding short-term risk, ABT is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, PHG has a market cap of 21B. Regarding current trading prices, ABT is priced at $133.26, while PHG trades at $22.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas PHG's P/E ratio is 75.57. In terms of profitability, ABT's ROE is +0.31%, compared to PHG's ROE of +0.03%. Regarding short-term risk, ABT is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, ABT is priced at $133.26, while ZBH trades at $91.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ZBH's P/E ratio is 20.33. In terms of profitability, ABT's ROE is +0.31%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, ABT is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ABT is priced at $133.26, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ABT's ROE is +0.31%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ALGN has a market cap of 13.3B. Regarding current trading prices, ABT is priced at $133.26, while ALGN trades at $183.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ALGN's P/E ratio is 33.29. In terms of profitability, ABT's ROE is +0.31%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SNN has a market cap of 12.8B. Regarding current trading prices, ABT is priced at $133.26, while SNN trades at $29.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SNN's P/E ratio is 31.02. In terms of profitability, ABT's ROE is +0.31%, compared to SNN's ROE of +0.08%. Regarding short-term risk, ABT is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABT is priced at $133.26, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABT's ROE is +0.31%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, ABT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, PEN has a market cap of 9.9B. Regarding current trading prices, ABT is priced at $133.26, while PEN trades at $254.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas PEN's P/E ratio is 235.68. In terms of profitability, ABT's ROE is +0.31%, compared to PEN's ROE of +0.04%. Regarding short-term risk, ABT is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, GMED has a market cap of 7.8B. Regarding current trading prices, ABT is priced at $133.26, while GMED trades at $57.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas GMED's P/E ratio is 43.15. In terms of profitability, ABT's ROE is +0.31%, compared to GMED's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, ABT is priced at $133.26, while BIO-B trades at $250.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, ABT's ROE is +0.31%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, ABT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BIO has a market cap of 6.4B. Regarding current trading prices, ABT is priced at $133.26, while BIO trades at $235.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BIO's P/E ratio is -3.08. In terms of profitability, ABT's ROE is +0.31%, compared to BIO's ROE of -0.32%. Regarding short-term risk, ABT is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BRKR has a market cap of 5.9B. Regarding current trading prices, ABT is priced at $133.26, while BRKR trades at $38.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BRKR's P/E ratio is 74.48. In terms of profitability, ABT's ROE is +0.31%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, ABT is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, GKOS has a market cap of 5.5B. Regarding current trading prices, ABT is priced at $133.26, while GKOS trades at $96.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas GKOS's P/E ratio is -42.65. In terms of profitability, ABT's ROE is +0.31%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, IRTC has a market cap of 4.8B. Regarding current trading prices, ABT is priced at $133.26, while IRTC trades at $151.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas IRTC's P/E ratio is -48.09. In terms of profitability, ABT's ROE is +0.31%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, ABT is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABT is priced at $133.26, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABT's ROE is +0.31%, compared to NARI's ROE of -0.18%. Regarding short-term risk, ABT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, TMDX has a market cap of 4.3B. Regarding current trading prices, ABT is priced at $133.26, while TMDX trades at $127.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas TMDX's P/E ratio is 90.45. In terms of profitability, ABT's ROE is +0.31%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, ABT is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, ABT is priced at $133.26, while ITGR trades at $119.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ITGR's P/E ratio is 55.41. In terms of profitability, ABT's ROE is +0.31%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, ABT is priced at $133.26, while INSP trades at $130.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas INSP's P/E ratio is 59.39. In terms of profitability, ABT's ROE is +0.31%, compared to INSP's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ABT is priced at $133.26, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ABT's ROE is +0.31%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ABT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, ABT is priced at $133.26, while PRCT trades at $58.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas PRCT's P/E ratio is -34.75. In terms of profitability, ABT's ROE is +0.31%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ABT is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, ABT is priced at $133.26, while LIVN trades at $45.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas LIVN's P/E ratio is -11.20. In terms of profitability, ABT's ROE is +0.31%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, ABT is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $133.26, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABT's ROE is +0.31%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, ABT is priced at $133.26, while UFPT trades at $233.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas UFPT's P/E ratio is 28.61. In terms of profitability, ABT's ROE is +0.31%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, ABT is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $133.26, while CNMD trades at $51.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CNMD's P/E ratio is 13.56. In terms of profitability, ABT's ROE is +0.31%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, ABT is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $133.26, while ATEC trades at $10.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ATEC's P/E ratio is -9.54. In terms of profitability, ABT's ROE is +0.31%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, ABT is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $133.26, while TNDM trades at $20.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas TNDM's P/E ratio is -7.25. In terms of profitability, ABT's ROE is +0.31%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, ABT is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $133.26, while AORT trades at $30.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas AORT's P/E ratio is -60.51. In terms of profitability, ABT's ROE is +0.31%, compared to AORT's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $133.26, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABT's ROE is +0.31%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, AHCO has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $133.26, while AHCO trades at $8.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas AHCO's P/E ratio is 14.34. In terms of profitability, ABT's ROE is +0.31%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $133.26, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABT's ROE is +0.31%, compared to SILK's ROE of -0.29%. Regarding short-term risk, ABT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $133.26, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABT's ROE is +0.31%, compared to FNA's ROE of -0.36%. Regarding short-term risk, ABT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SSII has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $133.26, while SSII trades at $5.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SSII's P/E ratio is -70.62. In terms of profitability, ABT's ROE is +0.31%, compared to SSII's ROE of -1.33%. Regarding short-term risk, ABT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ESTA has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $133.26, while ESTA trades at $36.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ESTA's P/E ratio is -11.72. In terms of profitability, ABT's ROE is +0.31%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, ABT is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, INMD has a market cap of 938.3M. Regarding current trading prices, ABT is priced at $133.26, while INMD trades at $13.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas INMD's P/E ratio is 6.05. In terms of profitability, ABT's ROE is +0.31%, compared to INMD's ROE of +0.25%. Regarding short-term risk, ABT is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, IART has a market cap of 903.8M. Regarding current trading prices, ABT is priced at $133.26, while IART trades at $11.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas IART's P/E ratio is -30.61. In terms of profitability, ABT's ROE is +0.31%, compared to IART's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABT is priced at $133.26, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABT's ROE is +0.31%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, IRMD has a market cap of 757.7M. Regarding current trading prices, ABT is priced at $133.26, while IRMD trades at $59.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas IRMD's P/E ratio is 38.45. In terms of profitability, ABT's ROE is +0.31%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ABT is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ABT is priced at $133.26, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CRY's P/E ratio is 425.71. In terms of profitability, ABT's ROE is +0.31%, compared to CRY's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SIBN has a market cap of 704M. Regarding current trading prices, ABT is priced at $133.26, while SIBN trades at $16.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SIBN's P/E ratio is -26.22. In terms of profitability, ABT's ROE is +0.31%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, ABT is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CBLL has a market cap of 668.3M. Regarding current trading prices, ABT is priced at $133.26, while CBLL trades at $18.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CBLL's P/E ratio is -14.79. In terms of profitability, ABT's ROE is +0.31%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, ABT is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABT is priced at $133.26, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABT's ROE is +0.31%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, AVNS has a market cap of 560.5M. Regarding current trading prices, ABT is priced at $133.26, while AVNS trades at $12.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas AVNS's P/E ratio is -1.47. In terms of profitability, ABT's ROE is +0.31%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, ABT is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, RXST has a market cap of 549.8M. Regarding current trading prices, ABT is priced at $133.26, while RXST trades at $13.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas RXST's P/E ratio is -20.50. In terms of profitability, ABT's ROE is +0.31%, compared to RXST's ROE of -0.10%. Regarding short-term risk, ABT is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, KIDS has a market cap of 510M. Regarding current trading prices, ABT is priced at $133.26, while KIDS trades at $20.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas KIDS's P/E ratio is -11.70. In terms of profitability, ABT's ROE is +0.31%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ABT is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BFLY has a market cap of 505.7M. Regarding current trading prices, ABT is priced at $133.26, while BFLY trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BFLY's P/E ratio is -6.82. In terms of profitability, ABT's ROE is +0.31%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SMLR has a market cap of 468.2M. Regarding current trading prices, ABT is priced at $133.26, while SMLR trades at $41.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SMLR's P/E ratio is -17.57. In terms of profitability, ABT's ROE is +0.31%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, ABT is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BFLY-WT has a market cap of 463.6M. Regarding current trading prices, ABT is priced at $133.26, while BFLY-WT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.31%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, AXGN has a market cap of 445.9M. Regarding current trading prices, ABT is priced at $133.26, while AXGN trades at $9.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas AXGN's P/E ratio is -61.19. In terms of profitability, ABT's ROE is +0.31%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BVS has a market cap of 432.7M. Regarding current trading prices, ABT is priced at $133.26, while BVS trades at $6.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BVS's P/E ratio is -13.58. In terms of profitability, ABT's ROE is +0.31%, compared to BVS's ROE of -0.21%. Regarding short-term risk, ABT is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, OFIX has a market cap of 423.2M. Regarding current trading prices, ABT is priced at $133.26, while OFIX trades at $10.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas OFIX's P/E ratio is -2.92. In terms of profitability, ABT's ROE is +0.31%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, ABT is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SRDX has a market cap of 414.7M. Regarding current trading prices, ABT is priced at $133.26, while SRDX trades at $29.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SRDX's P/E ratio is -20.71. In terms of profitability, ABT's ROE is +0.31%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, ABT is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CTKB has a market cap of 396.4M. Regarding current trading prices, ABT is priced at $133.26, while CTKB trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CTKB's P/E ratio is -34.78. In terms of profitability, ABT's ROE is +0.31%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SENS has a market cap of 377.1M. Regarding current trading prices, ABT is priced at $133.26, while SENS trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SENS's P/E ratio is -4.55. In terms of profitability, ABT's ROE is +0.31%, compared to SENS's ROE of -7.46%. Regarding short-term risk, ABT is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, TMCI has a market cap of 361.1M. Regarding current trading prices, ABT is priced at $133.26, while TMCI trades at $5.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas TMCI's P/E ratio is -6.75. In terms of profitability, ABT's ROE is +0.31%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, ABT is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, PACB has a market cap of 355.6M. Regarding current trading prices, ABT is priced at $133.26, while PACB trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas PACB's P/E ratio is -0.43. In terms of profitability, ABT's ROE is +0.31%, compared to PACB's ROE of -1.70%. Regarding short-term risk, ABT is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, NPCE has a market cap of 346.7M. Regarding current trading prices, ABT is priced at $133.26, while NPCE trades at $10.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas NPCE's P/E ratio is -12.89. In terms of profitability, ABT's ROE is +0.31%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, ABT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, VREX has a market cap of 324.9M. Regarding current trading prices, ABT is priced at $133.26, while VREX trades at $7.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas VREX's P/E ratio is -7.60. In terms of profitability, ABT's ROE is +0.31%, compared to VREX's ROE of -0.08%. Regarding short-term risk, ABT is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CLPT has a market cap of 321.1M. Regarding current trading prices, ABT is priced at $133.26, while CLPT trades at $11.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CLPT's P/E ratio is -14.95. In terms of profitability, ABT's ROE is +0.31%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, ABT is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, NNOX has a market cap of 315.6M. Regarding current trading prices, ABT is priced at $133.26, while NNOX trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas NNOX's P/E ratio is -5.44. In terms of profitability, ABT's ROE is +0.31%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, ABT is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, OM has a market cap of 306.2M. Regarding current trading prices, ABT is priced at $133.26, while OM trades at $17.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas OM's P/E ratio is -0.60. In terms of profitability, ABT's ROE is +0.31%, compared to OM's ROE of -1.45%. Regarding short-term risk, ABT is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CATX has a market cap of 305.1M. Regarding current trading prices, ABT is priced at $133.26, while CATX trades at $4.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CATX's P/E ratio is -3.34. In terms of profitability, ABT's ROE is +0.31%, compared to CATX's ROE of -0.27%. Regarding short-term risk, ABT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SNWV has a market cap of 286.3M. Regarding current trading prices, ABT is priced at $133.26, while SNWV trades at $33.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SNWV's P/E ratio is -5.37. In terms of profitability, ABT's ROE is +0.31%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, ABT is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, PTHL has a market cap of 282.2M. Regarding current trading prices, ABT is priced at $133.26, while PTHL trades at $19.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas PTHL's P/E ratio is -396.00. In terms of profitability, ABT's ROE is +0.31%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, ABT is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, VMD has a market cap of 263.6M. Regarding current trading prices, ABT is priced at $133.26, while VMD trades at $6.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas VMD's P/E ratio is 22.23. In terms of profitability, ABT's ROE is +0.31%, compared to VMD's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CERS has a market cap of 256.2M. Regarding current trading prices, ABT is priced at $133.26, while CERS trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CERS's P/E ratio is -13.40. In terms of profitability, ABT's ROE is +0.31%, compared to CERS's ROE of -0.35%. Regarding short-term risk, ABT is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, QTRX has a market cap of 244.8M. Regarding current trading prices, ABT is priced at $133.26, while QTRX trades at $6.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas QTRX's P/E ratio is -5.08. In terms of profitability, ABT's ROE is +0.31%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, ABT is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ZIMV has a market cap of 241.5M. Regarding current trading prices, ABT is priced at $133.26, while ZIMV trades at $8.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ZIMV's P/E ratio is -9.61. In terms of profitability, ABT's ROE is +0.31%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, ABT is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, MASS has a market cap of 238.5M. Regarding current trading prices, ABT is priced at $133.26, while MASS trades at $6.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas MASS's P/E ratio is -3.00. In terms of profitability, ABT's ROE is +0.31%, compared to MASS's ROE of -0.13%. Regarding short-term risk, ABT is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, TCMD has a market cap of 236.4M. Regarding current trading prices, ABT is priced at $133.26, while TCMD trades at $10.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas TCMD's P/E ratio is 15.41. In terms of profitability, ABT's ROE is +0.31%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, ABT is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, MXCT has a market cap of 230.2M. Regarding current trading prices, ABT is priced at $133.26, while MXCT trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas MXCT's P/E ratio is -5.41. In terms of profitability, ABT's ROE is +0.31%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, ABT is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, SGHT has a market cap of 224.4M. Regarding current trading prices, ABT is priced at $133.26, while SGHT trades at $4.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas SGHT's P/E ratio is -4.43. In terms of profitability, ABT's ROE is +0.31%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, ABT is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABT is priced at $133.26, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABT's ROE is +0.31%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BWAY has a market cap of 215.1M. Regarding current trading prices, ABT is priced at $133.26, while BWAY trades at $11.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BWAY's P/E ratio is 51.74. In terms of profitability, ABT's ROE is +0.31%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ABT is priced at $133.26, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas EYES's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.31%, compared to EYES's ROE of -0.26%. Regarding short-term risk, ABT is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BDMD has a market cap of 204M. Regarding current trading prices, ABT is priced at $133.26, while BDMD trades at $5.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BDMD's P/E ratio is 11.65. In terms of profitability, ABT's ROE is +0.31%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, BSGM has a market cap of 203.1M. Regarding current trading prices, ABT is priced at $133.26, while BSGM trades at $7.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas BSGM's P/E ratio is -14.04. In terms of profitability, ABT's ROE is +0.31%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, ABT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, TLSI has a market cap of 200.2M. Regarding current trading prices, ABT is priced at $133.26, while TLSI trades at $5.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas TLSI's P/E ratio is -4.81. In terms of profitability, ABT's ROE is +0.31%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, ABT is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, PROF has a market cap of 180.6M. Regarding current trading prices, ABT is priced at $133.26, while PROF trades at $6.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas PROF's P/E ratio is -4.97. In terms of profitability, ABT's ROE is +0.31%, compared to PROF's ROE of -0.70%. Regarding short-term risk, ABT is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, INGN has a market cap of 179.3M. Regarding current trading prices, ABT is priced at $133.26, while INGN trades at $6.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas INGN's P/E ratio is -5.80. In terms of profitability, ABT's ROE is +0.31%, compared to INGN's ROE of -0.15%. Regarding short-term risk, ABT is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ELMD has a market cap of 178.5M. Regarding current trading prices, ABT is priced at $133.26, while ELMD trades at $21.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ELMD's P/E ratio is 26.94. In terms of profitability, ABT's ROE is +0.31%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, ABT is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ANIK has a market cap of 156.6M. Regarding current trading prices, ABT is priced at $133.26, while ANIK trades at $10.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ANIK's P/E ratio is -14.56. In terms of profitability, ABT's ROE is +0.31%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, CVRX has a market cap of 149.1M. Regarding current trading prices, ABT is priced at $133.26, while CVRX trades at $5.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas CVRX's P/E ratio is -2.67. In terms of profitability, ABT's ROE is +0.31%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, ABT is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, LNSR has a market cap of 145.7M. Regarding current trading prices, ABT is priced at $133.26, while LNSR trades at $12.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas LNSR's P/E ratio is -2.52. In terms of profitability, ABT's ROE is +0.31%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, ABT is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, AVR has a market cap of 141.7M. Regarding current trading prices, ABT is priced at $133.26, while AVR trades at $3.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas AVR's P/E ratio is -1.10. In terms of profitability, ABT's ROE is +0.31%, compared to AVR's ROE of -2.92%. Regarding short-term risk, ABT is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, RPID has a market cap of 138.9M. Regarding current trading prices, ABT is priced at $133.26, while RPID trades at $3.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas RPID's P/E ratio is -3.08. In terms of profitability, ABT's ROE is +0.31%, compared to RPID's ROE of -0.56%. Regarding short-term risk, ABT is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, RCEL has a market cap of 135.9M. Regarding current trading prices, ABT is priced at $133.26, while RCEL trades at $5.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas RCEL's P/E ratio is -2.35. In terms of profitability, ABT's ROE is +0.31%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, ABT is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, LUCD has a market cap of 128.2M. Regarding current trading prices, ABT is priced at $133.26, while LUCD trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas LUCD's P/E ratio is -1.01. In terms of profitability, ABT's ROE is +0.31%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, ABT is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, OWLT has a market cap of 123.3M. Regarding current trading prices, ABT is priced at $133.26, while OWLT trades at $7.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas OWLT's P/E ratio is -4.63. In terms of profitability, ABT's ROE is +0.31%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, ABT is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, LUNG has a market cap of 103.5M. Regarding current trading prices, ABT is priced at $133.26, while LUNG trades at $2.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas LUNG's P/E ratio is -1.78. In terms of profitability, ABT's ROE is +0.31%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, ABT is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, MGRM has a market cap of 100.5M. Regarding current trading prices, ABT is priced at $133.26, while MGRM trades at $2.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas MGRM's P/E ratio is -5.63. In terms of profitability, ABT's ROE is +0.31%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, ABT is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, ICAD has a market cap of 100.3M. Regarding current trading prices, ABT is priced at $133.26, while ICAD trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas ICAD's P/E ratio is -19.21. In terms of profitability, ABT's ROE is +0.31%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 231.9B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ABT is priced at $133.26, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 17.28, whereas HJLI's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.31%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.